ArticleCancer cell international2014
PTOP and TRF1 help enhance the radio resistance in breast cancer cell.
Article in Cancer cell international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics.Experimental hematology & oncology · 2025Review
- Prognostic value of TERF1 expression in prostate cancer.Journal of the Egyptian National Cancer Institute · 2021Article
- Role of POT1 in Human Cancer.Cancers · 2020Review
- Identification of Integrin β1 as a Novel PAG1-Interacting Protein Involved in the Inherent Radioresistance of Human Laryngeal Carcinoma.Journal of Cancer · 2018Article
- UBE2D3 gene overexpression increases radiosensitivity of EC109 esophageal cancer cells in vitro and in vivo.Oncotarget · 2016Article
- Knockdown of telomeric repeat binding factor 2 enhances tumor radiosensitivity regardless of telomerase status.Journal of cancer research and clinical oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe telomere binding proteins play an important role in telomere function, which contribute greatly to the radio resistant in human cancers. This research is designed to investigate the relationship among the telomere length, telomerase activity and changes of telomere binding protein PTOP and TRF1 in radio resistant breast cancer cell lines.
methodsIrradiate MDA-MB-435 s breast cancer cell with total dose of 60 Gy delivered in 2 Gy/fraction and 6 Gy/fraction respectively, then measuring their telomere length by Southern blot analysis,telomerase activity by Telomerase PCR Elisa and detecting the expression of PTOP and TRF1 in both gene and protein levels. To further investigate the function of PTOP, using lentivirus technic to silence the PTOP gene and the detected the new silenced cells by southern blot and telomerase activity.
results2 radio resistant breast cancer cell lines were successfully established. The MDA-MB-435 s R60/6 was (approximate 8.1-8.6 kbp) about 2-2.4 folds to the patent cell (3.6-4.2 kbp), the MDA-MB-435 s R60/2 cell (approximate 5.3-6.3 kbp) was about 1.3-1.75 fold to the parent cell line. The telomerase activity was more enhanced in radio resistant cell lines than the parent cell. The expression of PTOP and TRF1 were significant increased in radio resistant cell lines than the patent cell in both gene and protein level. Otherwise, after using lentivirus technic to silence the PTOP gene, we found the radio resistant cell lines were significant decrease their radio resistances and telomerase activities.
conclusionThe telomere binding protein PTOP and TRF1 were increased expressed in radio resistant breast cancer cell, PTOP was observed instinct positive correlated with telomere lengthen and telomerase activity enhancement.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.